| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Jilin Aodong Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.52 |
| 52 Week High | CN¥18.17 |
| 52 Week Low | CN¥13.13 |
| Beta | 0.46 |
| 1 Month Change | -4.16% |
| 3 Month Change | 1.89% |
| 1 Year Change | -10.76% |
| 3 Year Change | -5.78% |
| 5 Year Change | -23.26% |
| Change since IPO | 374.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 623 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.5% | -4.2% | -4.9% |
| 1Y | -10.8% | -19.0% | -21.1% |
Return vs Industry: 000623 exceeded the CN Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: 000623 exceeded the CN Market which returned -21.1% over the past year.
Price Volatility
| 623 volatility | |
|---|---|
| 623 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 000623 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000623's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 5,399 | Shuqin Guo | www.jlaod.com |
Jilin Aodong Pharmaceutical Group Co., Ltd. produces and sells pharmaceutical products in China. The company offers various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine.
Jilin Aodong Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 623 fundamental statistics | |
|---|---|
| Market cap | CN¥17.45b |
| Earnings (TTM) | CN¥1.46b |
| Revenue (TTM) | CN¥3.45b |
12.0x
P/E Ratio5.1x
P/S RatioIs 623 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 623 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.45b |
| Cost of Revenue | CN¥1.75b |
| Gross Profit | CN¥1.70b |
| Other Expenses | CN¥238.06m |
| Earnings | CN¥1.46b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 49.23% |
| Net Profit Margin | 42.33% |
| Debt/Equity Ratio | 10.9% |
How did 623 perform over the long term?
See historical performance and comparison